Expertise in
2
conditions

Ella Willenbacher

Innsbruck, AT 
Expertise in
2
conditions
Innsbruck, AT 

Overview

Ella Willenbacher practices practicing medicine in Innsbruck, Austria.

Ms. Willenbacher is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Polycythemia Vera, Multiple Myeloma, B-Cell Lymphoma, and Non-Hodgkin Lymphoma.

She is actively involved in clinical research, co-authoring 33 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Innsbruck, 6020, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial DEFENCE (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial DEFENCE (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Enrollment Status: Completed
Publish Date: February 11, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 2
Phase II Single-arm Window-of-opportunity Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase II Single-arm Window-of-opportunity Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: February 16, 2022
Intervention Type: Drug
Study Drugs: Venetoclax, Obinutuzumab
Study Phase: Phase 2
View 1 Less Clinical Trial

33 Total Publications

Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q.
Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q.
Journal: Cancers
Published: February 20, 2025

Frequently Asked Questions about Ella Willenbacher

Is Ella Willenbacher a top-rated expert for Polycythemia Vera?

MediFind is an objective health platform that identifies experts based on real-world data. Ella Willenbacher is classified as an Advanced expert for Polycythemia Vera, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ella Willenbacher participate in research or clinical trials?

Yes. Ella Willenbacher has published 33 articles and abstracts on conditions like Polycythemia Vera. You can view a list of Ella Willenbacher's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Willenbacher's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile